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Background: Home treatment of patients with acute deep vein thrombosis (DVT) leads to cost savings and improved
quality of life. However, little information is known about what influences the clinical outcome in these patients.
Methods: The Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) is an ongoing registry of consecutive
patients with symptomatic, objectively confirmed, acute DVT or pulmonary embolism (PE). In this analysis evaluated the
clinical outcome <15 days of the start of therapy of all enrolled outpatients with acute DVT in the lower limbs.
Results: During the study period, 124 (2.8%) of 4405 DVT patients had at least one adverse event (symptomatic PE, 15;
recurrent DVT, 18; major bleeding, 37; death, 68). On multivariate analysis, bilateral DVT, renal insufficiency, body
weight <70 kg, recent immobility, chronic heart failure, and cancer were associated with an increased risk for adverse
events. When these variables were added into the derivation sample, the area under receiver operator characteristic (ROC)
curve was 0.81 (95% confidence interval [CI], 0.76 to 0.86). Patients with a risk score of <2 had a 1.2% incidence of
adverse events (23 in 1935 patients) compared with the 6.8% incidence in high-risk patients. In the validation sample, the
area under ROC curve was 0.79 (95% CI, 0.70 to 0.88). Low-risk patients had a 1.0% incidence of adverse events, and
those at high-risk had a 4.7% incidence.
Conclusion: A simple risk score based on easily available variables can identify DVT outpatients at low risk for an adverse
outcome. This information may help clinicians to decide which DVT patients may be eligible for ambulatory treatment.
(J Vasc Surg 2006;44:789-93.)Outpatient administration of low-molecular-weight hep-
arin (LMWH) is at least as effective and safe as traditional
inpatient therapy with unfractionated heparin (UFH) in pa-
tients with acute deep vein thrombosis (DVT) of the lower
limbs.1-3 Indeed, the Seventh American College of Chest
Physicians Consensus Guidelines recommend that patients
with acute DVT receive initial treatment with subcutaneous
LMWH instead of UFH as an outpatient, if possible.4 DVT
remains a potentially fatal disease, however, and some
patients will inevitably have an adverse outcome during
home therapy. Thus, reliable information on the factors
that determine prognosis in patients with acute DVT might
help clinicians decide about the appropriateness of outpa-
tient treatment. In addition, early detection and prompt
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with an alternative treatment and supportive measures
might reduce mortality.
The Registro Informatizado de la Enfermedad
TromboEmbólica (RIETE) registry is an ongoing, interna-
tional (Spain, France, Italy, Argentina), multicentre, pro-
spective registry of consecutive patients presenting with
symptomatic acute venous thromboembolism (VTE) con-
firmed by objective tests.5-9 We retrospectively analyzed
the clinical characteristics and 15-day clinical outcome of all
consecutive outpatients with acute DVT of the lower limbs,
trying to identify characteristics associated with adverse
events, defined as symptomatic PE, recurrent DVT, major
bleeding or death. We then generated a simple risk score to
discriminate patients at low or high risk for the composite
outcome.
PATIENTS AND METHODS
Patient entry criteria. Participating hospitals in the
RIETE registry prospectively enroll consecutive patients
with symptomatic, acute DVT or PE confirmed by objec-
tive tests including contrast venography, compression ul-
trasonography (CUS), impedance plethysmography, or
computed tomography (CT) scan for suspected DVT; and
pulmonary angiography, lung scintigraphy, or helical CT
scan, for suspected PE. All patients provide oral consent to
their participation in the registry, according to the require-
ments of the ethics committee within each hospital. For this
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considered.
Variables. The major outcome was the development of
symptomatic, objectively confirmed PE, recurrent DVT, ma-
jor bleeding, or death during the first 15 days of therapy. The
variables recorded by the registry comprise details of each
patient’s baseline characteristics; clinical status, including any
coexisting or underlying conditions such as chronic heart or
lung disease, recent (30 days before DVT diagnosis), major
bleeding, creatinine clearance; use of concomitant drugs, clin-
ical characteristics of the thrombotic event, treatment received
upon DVT diagnosis (type, dose, and duration), and out-
come. Immobilized patients are defined in this analysis as
nonsurgical patients who had been immobilized (ie, total bed
rest with bathroom privileges) for 4 days in the 2-month
period before PE diagnosis. The Cockcroft and Gault10 for-
mula was used to estimate creatinine clerance.10 The value for
the first serum creatinine measured after DVT diagnosis was
the one used to calculate creatinine clearance.
Follow-up. Each episode of clinically suspected recur-
rent DVT or PE was documented by repeat CUS, venog-
raphy, lung scanning, helical CT scan, or pulmonary an-
giography. The criteria for recurrent DVT were a new
noncompressible vein segment on CUS, a4-mm increase
in vein diameter of a previous thrombus at the popliteal or
common femoral vein on CUS, or an extension of a previ-
ous filling defect or a new intraluminal filling defect that
was viewed in at least two projections on venography.
Bleeding complications were classified as “major” if they were
overt and were associated with a decrease in the hemoglobin
level of 2.0 g/dL (20 g/L), required a transfusion of 2
units of blood, or were retroperitoneal or intracranial.
Statistical analysis. The commercial software package
SPSS 11.5 (SPSS Inc, Chicago, Ill) was used to calculate
odds ratios and corresponding 95% confidence intervals
(CI), and a P .05 was considered to be statistically signif-
icant. The significance of a number of variables on the risk
of developing the composite event of symptomatic PE, re-
current DVT, major bleeding, or death was tested by fitting
bivariate logistic regression. Candidate variables were based
on published literature and on expert opinion. A multivar-
iate logistic regression analysis was done to determine the
independent nature of the variables and was adjusted for
other characteristics to predict any adverse event. Signifi-
cance level of P  0.10 was considered to include and
exclude variables in the final multivariate model.
We constructed a risk scoring system in which we assigned
points to each risk factor according to the regression coeffi-
cients , rounding to the nearest integer. A risk score was
assigned to each subject by totalling the points for each risk
factor present. We also performed a receiver operating char-
acteristic (ROC) curve analysis,11 and computed the area
under the ROC curve and its corresponding 95% CI. We
selected the best cutoff score, discriminating between low-risk
and high- risk patients for adverse events. We performed a
cross-validation procedure by selecting the sample randomly
into 2947 patients (67%) for the derivation sample and 1458
(33%) patients for the internal validation sample.RESULTS
As of June 2005, 4405 consecutive outpatients with
acute DVT in the lower limbs were enrolled at 103 partic-
ipating hospitals, of whom 1059 (24%) were treated with-
out hospital admission. Symptomatic DVT diagnosis was
confirmed with CUS in 4099 patients, contrast venography
in 287, CT scan in 18, and impedance plethysmography in
one patient.
Clinical outcomes. During the study period, 138 ad-
verse events developed in 124 patients (2.8%): 15 (0.3%)
had symptomatic PE, 18 (0.4%) had recurrent DVT, 37
(0.8%) had major bleeding, and 68 (1.5%) died. The causes
of death were disseminated malignancy in 15 patients, fatal
bleeding in 8, fatal PE in 2, respiratory insufficiency (with-
out any objective test to rule out PE) in 7, unknown in 24,
other causes in 12. Two of the 15 patients with PE, six with
recurrent DVT, and two with major bleeding were treated
out of hospital. One of the two patients who bled at home
was a 74 year-old woman with no known risk factors for
VTE and no underlying diseases. An intracerebral hemor-
rhage developed 3 days after start of LMWH therapy, and
the patient died 4 days later.
Adverse events occurred in 69 patients during initial
therapy (68 were receiving LMWH therapy, one was receiv-
ing UFH). The percentage of these patients who received
infratherapeutic or supratherapeutic doses of LMWH was
similar to that in patients with no adverse events, as shown
in Table I. Afterwards, 55 patients had adverse events
during long-term therapy, of whom 19 were receiving
long-term LMWH, 20 had switched to antivitamin K
drugs, and 16 were still taking both drugs.
In the univariate analysis, age 65 years, body weight
70 kg, cancer, prior immobility, chronic heart failure,
renal insufficiency, recent major bleeding, use of cortico-
steroids, proximal DVT, and bilateral DVT were associated
with an increased risk for adverse events (Table I). Multi-
variate analysis confirmed that only body weight 70 kg,
cancer, prior immobility, chronic heart failure, renal insuf-
ficiency, and bilateral DVT were independently associated
with an increased risk for adverse events, both in the
derivation and the validation samples (Table II).
Clinical score. When these six independent variables
were added into the derivation sample to form the risk
score, the area under ROC curve was 0.81 (95% CI, 0.76 to
0.86). The best cut-off score for discriminating an adverse
event was ’3 points (sensitivity, 65.2; specificity, 77.7;
positive predictive value, 8.6%; negative predictive value,
98.6%). Patients with a score of2 had a 1.2% incidence of
adverse events (23 in 1935 patients), and they were iden-
tified as low-risk, compared with the 6.8% incidence in
high-risk patients (score 3), as summarized in Table III.
When we cross-validated this predictive model into the
validation sample, the area under ROC curve was 0.79
(95% CI, 0.70 to 0.88) with similar predictive characteris-
tics (sensitivity, 59.4; specificity, 78.1; positive predictive
value, 5.7%; negative predictive value, 98.8%). Low-risk
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incidence (22 in 473 patients).
DISCUSSION
Our data, obtained from a large prospective series of
Table I. Univariate analysis of the risk to develop an adve
Adverse events
(n  124) (%)
Clinical characteristics
Gender (males) 63 (51)
Age  65 years 89 (72)
Body weight 70 kg 68 (55)
Risk factors for VTE
Previous VTE 13 (11)
Cancer 64 (52)
Surgery 10 (8.0)
Immobility 4 days 55 (44)
Underlying diseases
Chronic lung disease 15 (12)
Chronic heart failure 14 (11)
CrCl 30 mL/min 19 (15)
30-60 mL/min 28 (23)
60 mL/min 77 (62)
Recent major bleeding 5 (4.0)
Antiplatelet therapy 12 (10)
NSAIDs 9 (7.3)
Corticosteroid therapy 18 (15)
Known thrombophilia 1 (0.8)
DVT characteristics
Bilateral involvement 13 (11)
Distal DVT 11 (8.9)
Initial therapy*
LMWH 121 (98)
LMWH, mean doses (IU/kg/day) 183  47
LMWH, doses
150 IU/kg/day 23 (19)
150-200 IU/kg/day 69 (57)
200 IU/kg/day 29 (24)
UFH 3 (2.4)
Thrombolytics 0
Inferior vena cava filter 2 (1.6)
OR, Odds ratio; CI, confidence intervals; VTE, venous thromboembolism;
deep vein thrombosis; LMWH, low-molecular-weight heparin; UFH, unfra
*Defined as overall death, symptomatic pulmonary embolism, recurrent DV
Table II. Multivariate predictors of the risk to develop an
of the clinical score
Variables
Derivation sample (N  294
OR (95% CI) P
Body weight 70 kg 1.5 (1.0-2.4) .0
Cancer 6.2 (3.9-9.8) .0
Bilateral DVT 3.3 (1.5-7.5) .0
Immobilization 4 days 2.8 (1.8-4.4) .0
CrCl 30 mL/min 8.0 (4.0-15.8) .0
CrCl 30-60 mL/min 4.1 (2.3-7.2) .0
Chronic heart failure 2.1 (0.9-4.7) .0
OR, Odds ratio; CI, confidence intervals; DVT, deep vein thrombosis; CrC
*Defined as overall death, symptomatic pulmonary embolism, recurrent DVconsecutive outpatients with acute, symptomatic DVT inthe lower limbs, were used to identify the main predictors
for adverse events 15 days of therapy. The elements
included in the score (ie, body weight 70 kg, cancer,
bilateral DVT, immobility 4 days, creatinine clearance,
and recent major bleeding) are easy to obtain in the clinical
ent* during the first 15 days of therapy
No adverse events
(n  4281) (%) OR (95% CI) P
2290 (53) 0.9 (0.6-1.3) NS
2633 (62) 1.6 (1.1-2.4) 0.02
1506 (35) 2.2 (1.6-3.2) .001
738 (17) 0.6 (0.3-1.0) NS
790 (19) 4.7 (3.3-6.8) .001
425 (10) 0.8 (0.4-1.5) NS
1062 (25) 2.4 (1.7-3.5) .001
386 (9.0) 1.4 (0.8-2.4) NS
140 (3.3) 3.8 (2.1-6.7) .001
102 (2.4) 7.4 (4.4-12.6)
301 (7.0) 3.9 (2.5-6.0)
3878 (91) 0.2 (0.1-0.2) .001
51 (1.2) 3.5 (1.4-8.9) 0.02
383 (8.9) 1.1 (0.6-2.0) NS
230 (5.4) 1.4 (3.7-2.8) NS
288 (6.7) 2.4 (1.4-3.9) 0.003
76 (1.8) 0.5 (0.02-3.0) NS
97 (2.3) 5.1 (2.7-9.3) .001
663 (16) 0.5 (0.3-1.03) 0.04
4204 (98) 0.7 (0.2-2.4) NS
176  39 — NS
846 (20)
2522 (60)
835 (20) — NS
74 (1.7) 1.4 (0.4-4.5) NS
3 (0.1) — NS
23 (0.5) 3.0 (0.7-13) NS
creatinine clearance; NSAIDs, nonsteroidal anti-inflammatory drugs; DVT,
ted heparin; NS, not significant.
major bleeding.
nt* during the first 15 days of therapy, and development
Validation sample (N  1458)
Point scoreOR (95% CI) P
1.9 (0.9-4.0) .10 1
2.2 (1.0-4.8) .05 4
4.4 (1.4-14.6) .01 2
2.1 (1.0-4.5) .05 2
4.5 (1.3-15.0) .02 4
4.0 (1.7-9.8) .02 3
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endorsement of outpatient therapy with LMWH for acute
DVT management,4 this approach was used in only 24% of
our patients. Similar rates were found in another registry
recently performed in the United States,12 thus suggesting
some doctors’ reluctance to send DVT patients home be-
cause of the feeling that the safety of this management
strategy has not yet been confirmed. In our experience, 24%
of recurrences and 5.4% of major bleeding episodes devel-
oped in patients being treated at home. Had their doctors
known that they were at an increased risk, the patients
probably would not have been allowed to have treatment at
home. Thus, we suggest that our score could be applied to
all outpatients with DVT to select those potentially eligible
for ambulatory therapy.
In the literature, cancer, renal insufficiency, recent ma-
jor bleeding, and immobility have been associated with a
worse prognosis in patients with DVT,13-16 but there is
some discrepancy on the influence of the location of throm-
bosis on the outcome. Although a cohort study of 355
patients with DVT found no difference in the rates of
recurrent DVT according to the location of thrombosis,17
another study found a greater than twofold higher rate in
patients with extensive iliofemoral DVT than in those with-
out iliac vein involvement.18 In other cohort studies of
patients with DVT, the location of thrombosis was not
investigated as a possible risk factor for recurrence.19-21
The main limitation of the present study is its design.
Because it was an observational study, it may contain some
sources of potential biases. First, in 93% of DVT patients,
the diagnosis was made by CUS, which has a variable
sensitivity for the detection of thrombi that involve the iliac
and the calf veins.21 Consequently, the prevalence of bilat-
eral DVT in the study population may have been underes-
timated.
A second limitation is the chosen time frame for
adverse events. The mean hospital stay for patients who
were admitted was 6  2 days; thus theoretically, the ideal
follow-up for this study would have to be 6 days. The
number of patients with adverse events during this short
period was too small, however, which is why we chose 15
days.
Definitive evidence to identify which patient character-
istics are associated with an adverse event could only be
obtained by a large prospective study in nonselected pa-
Table III. Application of the clinical score
Points Risk category Patients, n (%)
Derivation sample (n  2947)
2 Low 1935 (66)
3 High 1012 (34)
Validation sample (n  1458)
2 Low 985 (68)
3 High 473 (32)tients. In the RIETE registry, selection bias was avoided byincluding consecutive patients with objectively confirmed,
symptomatic, acute VTE who were referred to study cen-
ters. Enrolled patients were treated according to standard
practice, and prospective follow-up was completed for all
patients. Objective criteria were strictly applied for the
diagnosis of initial and recurrent VTE, including contrast
venography and pulmonary angiography if indicated, and
major bleeding was classified according to widely accepted
and validated criteria.
CONCLUSION
We used easily available information to develop a sim-
ple score that is able to discriminate between patients with
low or high risk for an adverse event during initial therapy
for DVT. Our data provide preliminary evidence that two
in every three outpatients with DVT belong to the low-risk
category, and are therefore eligible for ambulatory treat-
ment.
We express our gratitude to the Registry Coordinating
Center, S & H Medical Science Service, for their logistic
and administrative support.
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